Radioactive drug tested to shrink prostate tumors before surgery
NCT ID NCT06066437
Summary
This study is testing whether a radioactive drug called 177Lu rhPSMA-10.1 is safe and effective when given to men with high-risk prostate cancer before they have surgery to remove the prostate. The first phase checks if the drug dose is safe, and if so, the second phase will test its effects when given alone or with standard hormone therapy. Researchers want to see if this treatment can reduce the cancer in the prostate before surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.